Genetic, epigenetic and transcriptional comparison of esophagus tumor‑associated and adjacent normal myofibroblasts. by Huliák, Ildikó et al.
ONCOLOGY REPORTS  41:  839-852,  2019
Abstract. Myofibroblasts (MFs) are present in healthy 
tissues and are also key components of the tumor microen-
vironment. In the present study a comparative analysis of 
MFs obtained from various gastrointestinal tumor tissues 
and from tumor-adjacent normal tissues of cancer patients 
was performed, with the aim to evaluate differences in MF 
morphology, gene expression profile and function. The goal 
was to correlate the observed morphological and functional 
variations with the underlying genetic and epigenetic back-
grounds. The mutation frequency of MFs was assessed by next 
generation sequencing. The transcript levels of cancer‑specific 
genes were determined by TaqMan array and quantitative poly-
merase chain reaction. Epigenetic modifications were analyzed 
by immunocytochemistry and western blotting. The migratory 
capacity of MFs was assessed by scratch assay, whereas matrix 
metalloproteinase expression and activity were obtained by 
quantitative polymerase chain reaction and zymography. The 
results of the present study demonstrate that MFs were present 
in an increased number and with altered morphology in tumor 
samples compared with the healthy tissue. Although the 
detected number of mutations in tumor-associated and normal 
tissue-derived MFs did not differ markedly, shifts in the 
level of specific acetylated and methylated histone proteins, 
namely decreased levels of trimethylated H3K9 and acety-
lated H4K16 were demonstrated in tumor-associated MFs. 
Transcript levels of several tumor‑specific genes involved in 
metastasis, regulation of cellular growth, apoptosis, as well 
as in hypoxia-angiogenesis were altered in tumor-derived MF 
cultures. Increased mRNA levels were obtained and activity of 
matrix metalloproteases in tumor-derived MFs and these cells 
also exhibited a higher migratory capacity compared with 
the normal MFs. In summary, the results of the present study 
indicate that tumor-associated MFs display an altered pheno-
type compared with healthy tissue derived counterparts. The 
results imply that epigenetic rather than genetic alterations are 
associated with the development of the distinct expressional 
and functional features, which define this MF phenotype in the 
tumor microenvironment.
Introduction
The tumor microenvironment is now recognized as a critical 
participant in cancer progression (1-4). In epithelial tumors, 
out of the various types of stromal cells, cancer-associated 
fibroblasts (CAFs) are the predominant subset. Of CAFs, 
myofibroblasts (MFs) constitute the most abundant subtype, 
occupying the majority of this particular niche (5,6). In MFs 
the characteristic features of smooth muscle cells and fibro-
blasts are combined, as MFs acquire the ability to contract due 
to the de novo expression of smooth muscle actin (α-SMA) 
and by the assembly of novel stress fibers (7,8), and also 
maintain the extracellular matrix (ECM) synthesizing and 
secreting functions of fibroblasts. MFs are also mediators of 
tumor development and metastasis. However, it is still under 
debate whether their stimulating effects on cancer cell inva-
sion are executed directly through paracrine interactions with 
tumor cells or they promote cancer cell spreading indirectly 
by rendering the ECM more permissive for dissemination 
via remodeling (9-12). MFs express cytokines, chemokines, 
growth factors, different collagens, fibronectin, various adhe-
sion molecules and matrix metalloproteases (MMPs), and 
secrete these molecules directly or within exosomes into the 
surrounding extracellular milieu (13,14). It has been proposed 
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that this secretome alone would not be competent enough to 
trigger cancer cell invasion, but it is definitely sufficient for 
intensive paracrine dialogues between stromal cells (9,10). 
On the other hand, as MFs can modulate the composition and 
deregulate the biomechanical features of stromal ECM; in 
part by overproducing various MMPs, which will ultimately 
degrade the matrix and sever cell-matrix interactions. These 
MF-induced actions would undoubtedly favour cell mobili-
zation and contribute to cancer progression (11,15). In fact, 
several studies verified that the appearance of MMPs in the 
tumor microenvironment is associated with increased cancer 
aggressiveness and bad prognosis (16,17).
Due to the pivotal role of stromal MFs in tumor develop-
ment and progression, targeting MFs may be a viable approach 
to fight cancer invasion and metastasis. Nevertheless, prior 
to establishing MF-targeting clinical trials, it is essential to 
understand the major genetic, transcriptional and functional 
features of MFs residing in tumor-affected as well as in 
normal tissues. This knowledge is absolutely necessary in 
order to identify the key mechanisms that primarily govern 
the contribution of MFs in tumor invasion (10,18). In line 
with this, a comparative study was performed on matched 
pairs of primary MF cultures, isolated from cancerous speci-
mens and from the tumor-adjacent normal tissues of patients 
diagnosed with different gastrointestinal cancers. Detailed 
knowledge on the modulated MF behavior of the human 
esophagus or other gastrointestinal regions is relevant not 
only in cancer progression and invasion, but also in various 
injuries, inflammation, repair as well as in gastro‑esophageal 
reflux disease (19).
Therefore, pure MF cell cultures were first established 
then genetic polymorphisms were analyzed, epigenetic 
marks and gene expression profiles of normal tissue- and 
tumor-derived MFs with a special emphasis on genes involved 
in tumorigenesis, invasion, matrix remodeling, cell migration 
or proliferation were compared. The present study's particular 
focus was to reveal whether any notable genetic, epigenetic or 
expressional variations could be identified that would account 
for the tumor promoting effects of tumor-associated MFs. 
Concomitantly, targeted genome analysis of the esophageal 
tumor sample was also conducted.
Materials and methods
Chemicals and solutions. General laboratory reagents were 
from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany) and 
Molar Chemicals Kft (Budapest, Hungary). Cell culture media 
and associated reagents were from Sigma-Aldrich (Merck 
KGaA), specific reagents for polymerase chain reaction (PCR) 
were from Thermo Fisher Scientific, Inc., (Waltham, MA, 
USA).
Ethics. The present study was approved by the Ethics 
Committee of the University of Szeged, (Szeged, Hungary). 
All patients gave informed consent.
Patients. Esophageal as well as cecum, sigmoid colon and 
rectum resections were performed on patients diagnosed 
with gastrointestinal cancer at the Department of Surgery, 
University of Szeged. The esophageal cancer patient was a 
71-year-old male, the cecum cancer patient was a 69-year-old 
female, sigmoid colon cancer patient was a 71-year-old male 
and the rectum cancer patient was a 65-year-old female. The 
patients were recruited between January 2007 and May 2010. 
The status of the patients was evaluated regarding clinico-
pathological features, histopathological parameters, the stage, 
grade as well as histological type of the tumor. Lymphatic 
vessel or vascular invasion and positive margins of resections 
were also assessed.
Tissue specimens. Tissue specimens were obtained intraopera-
tively during cancer resection. Specimens were taken from the 
tumor tissues and also from the adjacent normal area (at least 
3-4 cm distant from the tumors).
Tissue specimens were evaluated following routine 
pathology procedures. These included passage from formalin 
into paraffin, sectioning, staining the 4‑µm thick sections with 
hematoxylin and eosin (5 min, room temperature), Giemsa 
technique (15 min, room temperature) and periodic acid-Schiff 
technique/Alcian blue (30 min, room temperature). Finally, 
immunostaining for α‑SMA (ab: cat. no. ms‑113; 1:800; Thermo 
Fisher Scientific, Inc.), vimentin (ab: cat. no. rm‑9120; 1:200; 
Thermo Fisher Scientific, Inc.) and desmin (ab: cat. no. ms‑376; 
1:100; Thermo Fisher Scientific, Inc.) was carried out using 
EnVision Flex system (Dako; Agilent Technologies, Inc., Santa 
Clara, CA, USA) according to the manufacturer's protocol. 
Sections were counterstained with hematoxylin at room 
temperature for 1 min. All slides were stained simultaneously 
using a computer-controlled autostainer (Ventana BenchMark 
Ultra, Ventana Medical Systems, Inc., Tucson, AZ, USA).
The images captured for histopathological assessment 
using a Zeiss Axiocam 506 color microscope and were 
analyzed using ImageJ 1.4.3.67 software (National Institutes 
of Health, Bethesda, MD, USA). Densitometry was performed 
to determine brown color intensity. Images were converted to 
RGB format and color-based thresholding was set as follows: 
Hue 0-136, saturation 57-255, brightness 0-255. On 8-bit 
images threshold was adjusted to 0-242, then particle analysis 
was performed.
Establishment of MF cultures. The isolation and culturing 
of normal as well as tumor-derived MFs was performed as 
described previously by Czepan et al (20). Briefly, normal 
tissue specimens and esophageal tumor tissue as well as cecum, 
sigmoid colon or rectum carcinoma samples were washed with 
1 mM DTT, incubated four times with 1 mM EDTA solution 
for 30 min, then placed into RPMI (Merck KGA) selection 
medium supplemented with 10% fetal bovine serum (FBS, 
Merck KGA); 1% penicillin‑streptomycin, 2% antibiotic‑anti-
mycotic solution. Following reaching confluence, the cells 
were trypsinized (0.25% trypsin‑EDTA) and were transferred 
into growth medium [Dulbecco's modified Eagle's medium 
(DMEM, Merck KGA) supplemented with 4 mM L-glutamine, 
10% FBS, 1% amino acid solution, 1% penicillin-streptomycin 
and 2% antibiotic-antimycotic solution]. Cells were cultured 
in 5% CO2 atmosphere at 37˚C. Aliquots were frozen in 
liquid nitrogen and used in the following experiments with 
care to minimize passage numbers. To monitor the purity of 
MF cultures, cells were stained for MF markers α-SMA and 
vimentin as previously described (20).
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Immunocytochemistry. For the detection of histone modi-
fications by immunostaining, 2x104 cells were seeded onto 
chamber slides (BD Biosciences, Franklin Lakes, NJ, USA) 
and were allowed to adhere overnight. Cells were fixed 
using 4% paraformaldehyde for 20 min at room tempera-
ture, permeabilized by adding PBS supplemented with 
0.3% Triton X‑100. Non‑specific protein binding sites were 
blocked in 5% bovine serum albumin (BSA; Sigma‑Aldrich; 
Merck KGaA) containing PBS and finally, cells were incu-
bated with primary antibodies for 2 h at room temperature. 
The used primary antibodies, their sources and the applied 
dilutions were: Pan-acetylated histone 3 (H3)-specific 
antibody (Bio‑Rad Laboratories, Inc., Hercules, CA, USA); 
cat. no. AHP412; diluted in 1:300 with 1% BSA containing 
PBS), anti-lysine 9 acetylated H3 antibody (Abcam, 
Cambridge, UK; cat. no. Ab4441; 1:750), antibody against 
H3K18ac (Abcam; cat. no. Ab1199; 1:500), anti‑H3K14ac anti-
body (Sigma‑Aldrich; Merck KGaA) cat. no. 06‑911; 1:450), 
antibody specific for lysine 8 acetylated histone 4 (Abcam; 
cat. no. Ab1760; 1:400), H4K12ac‑specific antibody (Abcam; 
cat. no. Ab1761; 1:300), antibody against H4K16ac (Abcam; 
cat. no. Ab1762; 1:300) and antibody to detect pan‑acetylated 
H4 (Sigma‑Aldrich; Merck KGaA; cat. no. 06‑598; 1:500). 
Antibodies specific for H3 di‑ and trimethylated at lysine 9 
were from Upstate (Merck KGaA; cat. no. 07‑521) and Abcam 
(cat. no. Ab8898) and used in 1:750 and 1:500 dilutions, 
respectively. Samples were incubated with the secondary anti-
body (Alexa Fluor 555‑conjugated anti‑rabbit IgG; Molecular 
Probes; Thermo Fisher Scientific, Inc.) at room temperature 
in the dark, for 1 h. For DNA labeling, 4,6-diamino-2-phe-
nylindole (DAPI) staining was performed (dilution 1:3,000 
in PBS solution, for 5 min). Following extensive washing 
in PBS, slides were covered with fluoromount mounting 
medium (Sigma‑Aldrich; Merck KGaA). Quantification of 
fluorescence intensity was performed using ImageJ 1.4.3.67 
software (National Institute of Health, Bethesda, MD, USA). 
Corrected total cell fluorescence (CTCF) was calculated based 
on fluorescence values from ~30 cells/sample according to the 
following formula: CTCF= integrated density-(area of selected 
cell x mean fluorescence of background readings).
Variant analysis. DNA variant analysis of selected tumor 
genes was performed by targeted sequencing on DNA samples 
derived from tumor-associated and normal MFs and from cells 
of the tumor mass. DNA was prepared using Macherey-Nagel 
NucleoSpin Tissue columns according to the manufacturer's 
protocol. Samples were quantitated by Qubit dsDNA BR assay 
kit (Thermo Fisher Scientific, Inc.) with a Qubit 2.0 fluorimeter. 
For each sample, 50 ng DNA was used to prepare Illumina 
sequencing libraries using Illumina TruSight Rapid Capture 
kit (Illumina, Inc., San Diego, CA, USA) with TruSight Cancer 
sequencing panel. The TruSight Cancer panel targets 94 genes 
and sites of 284 single nucleotide polymorphisms (SNPs) asso-
ciated with tumors. The gene list of the TruSight Cancer panel 
is available online on the manufacturer's website (https://emea.
illumina.com/content/dam/illumina-marketing/documents/prod-
ucts/gene_lists/gene_list_trusight_cancer.xlsx). Sequencing 
libraries were prepared by the TruSight Rapid Capture workflow 
and quality tested by capillary electrophoresis on an Agilent 
Bioanalyzer 2100 instrument with Agilent High Sensitivity 
DNA chip (Agilent Technologies). Pooled mixtures of indexed 
libraries were denatured and sequenced with Illumina MiSeq 
using Reagent kit V2-300. Variants were called by MiSeq 
Report (MSR) enrichment workflow of the BaseSpace cloud 
computing environment. Vcf files containing the identified 
variants were annotated using Illumina VariantStudio 2.1.46 
software (Illumina, Inc.) with the following annotation sources: 
Variant Effect Predictor, v2.8; 1000 Genomes (April 2012 v3); 
Cosmic (v65); ClinVar (September 5, 2013); dbSNP (v137); 
NHLBI Exome Variant Server (vESP6500SI‑V2); USCS (hg19).
RNA extraction. Total RNA was isolated from confluent MF 
cultures with TRIzol reagent (Invitrogen; Thermo Fisher 
Scientific, Inc.) using the manufacturer's protocol, followed by 
removal of DNA contamination with DNase I (Thermo Fisher 
Scientific, Inc.). Total RNA from Hker E6SFM human kerati-
nocytes was a gift from Dr. Vilmos Tubak (Creative Laboratory 
Ltd., Szeged, Hungary). Quality of total RNA was assessed 
using Agilent Bioanalyzer 2100 (Agilent Technologies).
TaqMan low‑density gene expression array. For gene 
expression the mRNA levels of 190 genes were analyzed 
simultaneously by reverse transcription-quantitative (RT-q)
PCR by TaqMan Low Density Array (TLDA; Applied 
Biosystems; Thermo Fisher Scientific, Inc.) using 384‑well 
microfluidic cards. Each sample was loaded in duplicates. In 
the TLDA experiments 600 ng RNA was reverse transcribed 
with a High Capacity Reverse Transcription kit (Thermo 
Fisher Scientific, Inc.) according to the manufacturer's 
protocol and cDNAs were mixed with TaqMan Universal PCR 
Master mix (Thermo Fisher Scientific, Inc.). UD‑GenoMed 
Medical Genomic Technologies Company (Debrecen, 
Hungary) has performed PCR amplifications using an ABI 
PRISM 7900HT real-time PCR system (Thermo Fisher 
Scientific, Inc.). PCR reaction cycles were: 2 min at 50˚C and 
10 min at 94.5˚C, followed by 40 cycles of 30 sec at 97˚C and 
1 min at 59.7˚C.
The genes included in the analysis were manually selected 
from TaqMan Gene Sets (https://products.appliedbiosystems.
com/ab/en/US/adirect/ab?cmd=catNavigate2&catID=604535). 
The expression levels were normalized to five internal 
controls; GAPDH, β-2-microglobulin, β-actin, 18S RNA and 
glucuronidase-β. Increases or decreases of 2-fold in the expres-
sion levels were considered as significant alterations.
Quantitative and conventional RT‑PCR. For quantitative 
and conventional RT‑PCR reactions first strand cDNA was 
synthesized from 1 µg total RNA obtained from MFs and 
from Hker E6SFM human keratinocytes used as control, with 
random hexamer primers using TaqMan Reverse Transcription 
Reagent (Applied Biosystems; Thermo Fisher Scientific, Inc.) 
according to the manufacturer's protocol.
Conventional PCR was carried out using GeneAmp PCR 
System 9700 (Thermo Fisher Scientific, Inc.). Thermal cycling 
was performed as follows: 5 min at 95˚C, 30 cycles of 95˚C 
for 20 sec, 60˚C for 40 sec and 72˚C for 45 sec. PCR prod-
ucts (10 µl of 30 µl total products per lane) were resolved on 
2% agarose gel and visualized using ethidium‑bromide.
qPCR reactions were carried out in duplicates in an 
ABI PRISM 7500 real-time thermocycler and Thermo 
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PikoReal 96 Real-Time PCR system using SYBR-Green 
chemistry (Maxima SYBR Green qPCR Master Mix 2X; 
K0252, Thermo Fisher Scientific, Inc.). The thermocycling 
conditions were the following: 1X (95˚C, 5 min); 40X (95˚C, 
15 sec ‑ 60˚C, 1 min). Individual quantification cycle (Cq) 
values were normalized to Cq values of an internal control 
gene (18S ribosomal RNA). The tumor-associated samples 
were compared with the appropriate controls following 
normalization. Alterations in the expression levels were 
calculated by the 2-ΔΔCq method (21). Primer sequences were 
as follows: Matrix metalloproteinase (MMP)1-F: 5'-GAT GTG 
GAG TGC CTG ATG TG‑3'; MMP1‑R: 5'‑CTG CTT GAC 
CCT CAG AGA CC‑3'; MMP2‑F: 5'‑ATG ACA GCT GCA 
CCA CTG AG-3', MMP2-R: 5'-ATT TGT TGC CCA GGA 
AAG TG-3', MMP3-F: 5'-GGC AGT TTG CTC AGC CTA 
TC‑3', MMP3‑R: 5'‑TCA CCT CCA ATC CAA GGA AC‑3'; 
MMP10-F: 5'-CAT ACC CTG GGT TTT CCT CCA A-3', 
MMP10-R: 5'-GTC CGC TGC AAA GAA GTA TGT TTT 
C‑3'; MMP12‑F: 5'‑GAT GCA CGC ACC TCG ATG T‑3'; 
MMP12-R: 5'-GGC CCC CCT GGC ATT-3', 18 SRNA-F: 
5'‑AAA CGG CTA CCA CAT CCA AG‑3'; 18 SRNA‑R: 5' 
CGC TCC CAA GAT CCA ACT AC-3'.
Protein extraction and western blotting. For preparation 
of whole cell protein extracts, confluent MF cultures were 
washed with PBS, cells were collected by scraping and lysed 
in loading buffer [60 mM Tris (pH 6.8), 2% SDS, 10% glyc-
erol, 5% β-mercaptoethanol, 0.002% bromophenolblue]. Total 
protein concentration of the samples was assessed by bicin-
choninic acid protein assay kit (Thermo Fisher Scientific, 
Inc.) prior adding bromophenolblue. A total of 15 µg protein 
of each sample was separated by SDS-PAGE on 15% gels 
and transferred onto nitrocellulose membrane (Amersham; 
GE Healthcare, Chicago, IL, USA). Membranes were 
incubated first in 5% non‑fat milk (in Tris‑buffered saline 
supplemented with 0.5% Tween-20) to block non-specific 
binding sites then with primary anti-histone antibodies 
specific for H4K16ac (Abcam; cat. no. Ab1762; 1:500) and 
H3K9me3 (Abcam; cat. no. Ab8898; 1:750). Detection of H4 
was used to verify equal loading. For this anti-H4 antibody 
(Abcam; cat. no. mab31827) was applied in 1:8,000 dilution. 
Incubation with horseradish peroxidase-conjugated IgG 
secondary antibodies (Dako; Agilent Technologies, Inc., 
anti‑rabbit IgG; cat. no. P0448; 1:2,000 for modified histones 
and anti‑mouse IgG, cat. no. P0260; 1:10,000 for H4) was 
performed at room temperature, for 50 min. Blots were devel-
oped with chemiluminescent HRP reagent (EMD Millipore, 
Billerica, MA, USA).
Assessment of MMP activity by gelatine zymography. The 
activities of the two gelatinolytic MMPs (MMP2 and MMP9) 
in cell lysates and in cell media were examined with gela-
tine zymography. MFs were lysed in 50 mM Tris pH 7.4, 
0.2% Triton X‑100 buffer by freeze‑thawing in liquid N2 and 
pressing through a 23 G needle. Following centrifugation 
(17,000 x g, 10 min, 4˚C), total protein concentration was 
measured by the Bradford method (Bio-Rad Laboratories, 
Inc.). To detect gelatinase activity in culture media, MFs 
were grown to 100% confluence in 75 cm2 flasks. Cells were 
serum starved for 24 h, then media were collected on ice and 
the proteins were precipitated by trichloroacetic acid in the 
presence of sodium-deoxycholate. The pellet was collected by 
centrifugation (17,000 x g, 30 min, 4˚C), washed with acetone 
and re-suspended in water (22).
A total of 10 µg protein samples were resolved on 
10% native PAGE co‑polymerized with gelatin (2.5 mg/ml, 
type A from porcine skin; Sigma‑Aldrich; Merck KGaA). 
Following electrophoresis, gels were washed 3 times for 
20 min with 2.5% Triton X-100 solution and incubated for 20 h 
at 37˚C in buffer containing 50 mM Tris‑HCl pH 7.4, 150 mM 
NaCl, 5 mM CaCl2 and 0.05% NaN3. Following incubation, 
gels were stained with Coomassie Brilliant Blue for 1 h and at 
room temperature and destained in 30% ethanol, 10% acetic 
acid solution.
Migration assay. A total of 2x105 cells were seeded onto 
six-well plates and allowed to grow overnight in growth 
medium. On the following day the confluent monolayer was 
gently scratched by a P2 tip in the middle of the well. Wounds 
were measured and images were captured under an inverted 
light microscope. Cultures were incubated at 37˚C for 24 h 
and migration of the cells was evaluated by counting the 
number of cells, which migrated into the wound area (20). The 
motility of tumor-derived MFs was expressed as percentage 
of the control MFs.
Statistics. Data are presented as mean ± standard error of 
the mean. Experiments were repeated 3 times using 3 inde-
pendent replicates. Statistical significance was determined 
using SigmaPlot Software version 12.0 (Systat Software, San 
Jose, CA, USA) with Student's t-test, Mann-Whitney U test 
or analysis of variance followed by Tukey's HSD post hoc 
multiple comparison test.
Results
Histological analysis of MFs in normal tissue and in the esoph‑
ageal tumor of a patient. The patient involved in the major part 
of the study is a 71-year-old male with a 42x39x7 mm esopha-
geal adenocarcinoma, which developed probably on a Barrett's 
esophagus background. Tumor grading was determined as 
pT3N1Mx, grade 2-3. Lymphatic and vascular invasion was 
identified. Sections of esophageal tumor and normal tissue, 
obtained from the patient, were stained for α-SMA, desmin and 
vimentin to inspect the number, morphology and localization 
of MFs. Representative α-SMA immunostainings on the tissue 
sections are presented in Fig. 1 (A, normal; B, tumor‑derived 
sample). Intensive brown staining indicates high expression of 
α-SMA, a feature characteristic to MFs. Pericytes and smooth 
muscle cells also express α-SMA, however, these cells can be 
recognized and distinguished from MFs based on their charac-
teristic morphology and on complementary immunostainings 
for desmin and vimentin (not shown).
The histological analysis concluded that the number of 
α-SMA- and vimentin-positive cells within the tumor was 
increased (Fig. 1B). Densitometrically quantified and normal-
ized MF‑specific brown color staining revealed significantly 
elevated (230%) color density in tumor-derived sections 
compared with the color intensity in adjacent normal tissue 
sections (set as 100%), indicating higher incidence of MF in 
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the tumor-derived sections (P<0.001, Student's t-test, data not 
shown). Furthermore, the spatial arrangement and distribution 
of MFs were also markedly different in the tumor environment 
compared with the normal tissue. MFs were demonstrated 
mostly around the crypts and were confined to pericryptal 
and subepithelial localization in normal tissue, whereas in the 
tumor tissue, apart from the highly elevated number and the 
greatly distorted shape of MFs, the arrangement of the cells 
was severely transformed, composing meshwork-like struc-
tures embedded in the tumor mass.
Genetic background, epigenetic modifications in MFs and 
targeted genome analysis of the tumor sample. To identify 
genetic alterations in MF cells and possible somatic variants in 
esophagus tumor-derived MFs targeted genome analysis was 
performed. The exonic sequences of 94 tumor-associated genes 
and 284 additional sites of tumor-associated SNPs included 
in the Illumina TruSight Cancer Panel, were determined by 
next generation deep sequencing. DNA sequences totaling 
of 255 kbp of samples obtained from normal tissue-derived 
and tumor-derived MF cells, and also from esophageal tumor 
tissue were determined. Sequencing data were analyzed and 
variants of interest were selected following annotation with 
Illumina VariantStudio software.
It was demonstrated that on the sequenced 255 kbp 
genomic region normal tissue-derived MFs of this patient 
carried 277 variants and identical number or variants were 
present in the tumor-associated MFs, while 282 variants were 
discovered in tumor tissue samples. Out of the 277 SNPs in 
MFs 22 (Table I) were predicted to be functionally significant, 
based on their effect on protein structure, by their ClinVar 
classification or presence in the COSMIC database, or by their 
predicted effect on protein function by Sift and/or PolyPhen 
analysis. These SNPs were located in the ALK receptor 
tyrosine kinase, BRCA2, epidermal growth factor receptor, 
ERCC excision repair 5 (ERCC5), exostosin glycosyltrans‑
ferase 1, FA complementation group I, FERM, ARH/RhoGEF 
and pleckstrin domain protein 2, HNF1 homeobox A, 
HRas proto‑oncogene, GTPase, mutL homolog 1, mutS 
homolog 6 (MSH6), PMS1 homolog 2, mismatch repair 
system component, patched 1, SLX4 structure‑specific endo‑
nuclease subunit (SLX4), tumor protein p53 (TP53), or TSC 
complex subunit 2 (TSC2) genes and each were present in a 
heterozygous state. A total of four genes ERCC5, BRCA2, 
MSH6 and SLX4 were affected each by more than one SNP, 
however, whether these represented mono- or diallelic state of 
these variants cannot be determined.
Next those variants that were present in lower frequency 
and only in the esophagus tumor-derived MFs or/and in the 
esophagus tumor sample but not in the adjacent normal MF 
samples (Table II) were identified in order to gain information 
on somatic mutation load in the tumor tissue, and tumor-asso-
ciated MFs. In the tumor-derived MF samples variants with 
5-7% allele frequency in the enhancer of zeste 2 polycomb 
repressive complex 2 subunit (EZH2; chr7: 148511066, C>A), 
TSC2 (chr16: 2120519, C>A) and folliculin (FLCN; chr17: 
17119708, T>TG) genes were identified. The SNPs affecting 
EZH2 and TSC2 caused missense mutations, the insertion 
in FLCN causes a frame-shift mutation and is described in 
the ClinVar and COSMIC database (id: COSM1381204) as a 
variant associated with the large intestine as primary tumor 
site. In the tumor tissue variants of the FA complementa‑
tion group D2 (FANCD2), XPC complex subunit, BRCA1 
associated protein 1 and glypican 3 were demonstrated with 
2-4% allele frequency and SNP of TP53 with allele frequency 
of 14.92%. The TP53 variant (chr17: 7577539, G>A) is present 
in the ClinVar and COSMIC databases (id: COSM10656) and 
is associated with Li-Fraumeni syndrome and tumors with 
various primary sites including the esophagus. The de novo 
somatic nature of most of these variants is supported by the 
fact that all of the relevant variants, except for a FANCD2 
variant in the tumor sample, have a 0% global allele frequency 
in the 1,000 Genomes Project database.
All combined, esophagus tumor-derived MFs demon-
strated 3, while the tumor sample exhibited 5 sequence 
variants not present in normal MFs. The low occurrence of 
somatic variants in MFs obtained from the tumor tissue and 
the observation that the normal tissue-derived MFs carried 
nearly the same numbers of unique somatic mutations suggest 
that mutation frequency is not elevated greatly in tumor-asso-
ciated MFs.
As no drastic difference in mutation frequency between 
tumor-derived MFs and MFs isolated from the normal tissue 
was detected, it was hypothesized that epigenetic modifications 
may be involved in the development of the observed morpho-
logical alterations, since epigenetic alterations can affect the 
Figure 1. Immunolocalization and morphological rearrangement of 
tumor-associated MFs. Representative α-smooth muscle actin immunostain-
ings of (A) normal and (B) tumor-derived sections are presented. Brown 
staining highlights MFs, pericytes and smooth muscle cells. MFs (indicated by 
arrows) are localized mostly around the crypts in the adjacent normal tissue. 
Note that in the tumor the number of MFs is markedly increased, their shape 
is distorted and their architecture is severely damaged. The scale bar in the left 
upper corner indicates 100 µm for both panels A and B. MF, myofibroblasts.
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expression profile and ultimately the morphology and the 
function of tumor-associated MFs. To substantiate this notion, 
a selected number of epigenetic markers were first examined 
by immunostaining. MFs were incubated with antibodies 
specific for pan‑acetylated H3 and H4 as well as with anti-
bodies recognizing specifically H3K9ac, H3K14ac, H3K18ac, 
H4K8ac, H4K12ac, H4K16ac, and di- and trimethylated H3K9. 
Immunostaining revealed significantly decreased global 
levels of trimethylated H3K9 and acetylated H4K16 (P<0.01; 
Fig. 2A) in the esophagus tumor-derived MFs compared to the 
adjacent normal MF cells. Immunoblots verified the results 
obtained by immunocytochemistry for selected histone modi-
fications, since western blotting also indicated lower levels of 
trimethylated H3K9 and acetylated H4K16 in tumor-derived 
MF cells (Fig. 2B). On the other hand, further differences in 
global histone modifications between MFs isolated from the 
tumor and from the adjacent normal tissue were not detected 
(data not shown).
Transcriptome analysis of tumor‑derived and normal MFs. 
As a further step to compare MFs obtained from normal 
and esophageal tumor tissue, whether any variations in the 
expression patterns of selected genes can also be identified 
was investigated. The mRNA levels of 190 chosen genes were 
compared on TaqMan low-density gene expression array. In 
the analysis genes associated with invasion, metastasis devel-
opment, angiogenesis, oxidative stress and apoptosis were 
included, as well as genes responsible for signaling pathway 
components [mitogen activated protein kinase, transforming 
growth factor (TGF)-β and wingless-type MMTV integration 
site family (WNT)]. Furthermore, the expression level of ECM 
elements including different types of collagens, basement 
membrane components and matrix remodeling factors were 
also examined.
Results of the arrays revealed that several genes involved in 
metastasis [C-X-C motif chemokine ligand 12 (CXCL12), endo‑
thelin 1 (EDN1), LY6/PLAUR domain containing 3 (LYPD3), 
MMP3 and plasminogen activator, urokinase (PLAU)], 
in regulation of cellular growth [cyclin D1 (CCND1), Fos 
proto‑oncogene (FOS), mitogen-activated protein kinase kinase 
kinase 8 (MAP3K8), myostatin (GDF8), uncoupling protein 2 
(UCP2) and WNT1‑inducible‑signaling pathway protein 1 
(WISP1)], in apoptosis (BCL2) as well as in hypoxia-angiogenesis 
[ectonucleotide pyrophosphatase/phosphodiesterase 2 (ENPP2), 
heme oxygenase 1 (HMOX1) and pleiotrophin (PTN)] demon-
strated altered expression in matching MF cultures derived from 
tumor and from the adjacent normal tissue (Table III). On the 
other hand, none of the collagen genes included in the TaqMan 
array (collagen I α1, collagen IV α1 and collagen XV α1) or 
any relevant ECM glycoproteins and proteoglycans exhibited 
altered expression in tumor-associated MFs compared with the 
cognate normal controls.
The detected elevated gene expression levels of CCND1, 
UCP2 and Wnt signaling pathway member WISP1 in 
tumor-derived MFs suggest a higher proliferation rate which 
can account for the increased MF cell number within the 
esophageal tumor mass. In contrast, lower levels of mRNAs 
corresponding to GDF8, FOS and MAP3K8 in tumor-associ-
ated MFs (Table III) were demonstrated.
In tumor-derived MFs higher expression level of metas-
tasis-associated factor endothelin 1, a secreted peptide, which 
has been demonstrated to stimulate cancer and stromal cell 
proliferation and migration within the tumor microenviron-
ment was observed. Similarly, elevated gene expression of 
MMP3 and PLAU was detected in tumor-associated MFs 
compared to normal tissue-derived MFs (Table III). On the 
other hand, TaqMan array data indicated lower expression of 
the chemokine CXCL12 and of LYPD3.
Finally, decreased expression of apoptosis-associated 
BCL2, as well as of hypoxia-angiogenesis-linked ENPP2, 
HMOX1 and PTN genes were detected in esophagus 
tumor-derived MFs compared with normal counterparts 
(Table III).
Figure 2. Histone acetylation and methylation profile in tumor‑associated 
and normal myofibroblasts. (A) Representative immunostaining images 
of H3K9me3 and H4K16ac modifications and the quantification of the 
fluorescence intensity (by ImageJ) are presented demonstrating that H3K9 
trimethylation and H4K16 acetylation level was significantly reduced in 
T compared with N cells. **P=0.006 for H3K9me3 and ***P<0.001 for 
H4K16ac, Mann-Whitney U test. (B) Immunoblots supported the observa-
tions of the immunocytochemistry, indicating lower levels of trimethylated 
H3K9 and acetylated H4K16 in the tumor-associated cells. H3K9me3, 
trimethylated histone 3 lysine 9; H4K16ac, acetylated histone 4 lysine 16; 
T, tumor‑associated; N, normal.
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Migration capacity and expression of MMPs in tumor‑de‑
rived MFs. As gene expression data indicated that a 
number of the genes exhibiting altered expression levels 
in tumor-associated MFs are involved in the regulation of 
cellular growth and metastasis, the expression analysis was 
extended to matrix-modifying factors. As MFs can secrete 
MMP enzymes into their surroundings, the MMP expres-
sion pattern of MFs was examined to see whether there is a 
difference in this respect between the esophageal tumor- and 
normal tissue-derived MFs.
Using RT‑qPCR significantly increased levels of mRNA 
corresponding to MMP3, MMP10 and MMP12 were detected 
in MFs isolated from the esophageal tumor compared with 
the normal tissue MFs (P<0.01), however no difference was 
demonstrated in MMP1 and MMP2 levels (Fig. 3A). Since 
the secreted gelatinase MMP2 localizes on the surface of the 
migrating cells (23) and accumulates mainly on the leading 
edge of invasive tumors (24), in‑gel zymography was used to 
test gelatinolytic activity in MF cell lysates and conditioned 
cell media. Although zymograms indicated no significant 
differences in MMP2 activities between cell lysates of esopha-
geal tumor-derived and normal tissue MFs, conditioned media 
of the tumor-associated cells exhibited markedly higher 
MMP2 activity compared with the medium of normal MFs 
(Fig. 3B). Altogether these results indicate that MFs in the 
tumor tissue are programmed to express and secrete higher 
amounts of various MMP enzymes than normal tissue residing 
counterparts. This feature can contribute to the capability of 
tumor stroma residing MFs of degrading pericellular ECM, as 
well as to promoting tumor invasion and metastasis.
In addition to the MMP expression profile and activity, 
the migratory capacity of esophageal tumor- and normal 
tissue-derived MFs was also investigated. For this, scratch 
wound assays were performed and the migratory activity of 
MFs within a 24-h time frame was compared (Fig. 3C). The 
motility of normal MFs was defined as 100% and expressed 
data obtained for tumor‑derived MFs was defined as normal-
ized migration rate. It was demonstrated that the tumor‑derived 
MFs migrated significantly more (153.09%±2.12) compared 
with their normal counterparts (100%±2.39; P<0.05; Fig. 3C), 
suggesting that an elevated migratory capacity is an acquired 
functional feature of the tumor-residing MF phenotype.
To verify that the observed functional differences between 
normal tissue and tumor-residing MFs populations of the same 
individual are not limited to one patient but can be considered 
widespread, and to draw a general conclusion from the results 
of the present study, additional MF cultures were established 
from tissue specimens of other patients bearing tumors in 
diverse regions of the gastrointestinal tract, namely indi-
viduals with cecum, sigmoid colon or rectum carcinoma. The 
Table III. Increased or decreased expression of specific genes in tumor‑associated versus adjacent normal MFs analyzed by 
TaqMan array.
1. Apoptosis Symbol log2 change
B-cell CLL/lymphoma 2 BCL2 -1.05
2. Hypoxia-angiogenesis associated Symbol log2 change
Ectonucleotide pyrophosphatase/phosphodiesterase 2 (autotaxin) ENPP2 -3.13
Heme oxygenase (decycling) 1 HMOX1 -1.37
Pleiotrophin PTN -1.28
3. Metastasis associated Symbol log2 change
Chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1) CXCL12 -212
Endothelin 1 EDN1  2.55
LY6/PLAUR domain containing 3 LYPD3 -1.17
Matrix metallopeptidase 3 (stromelysin 1, progelatinase) MMP3  2.26
Plasminogen activator, urokinase PLAU  1.07
4. Regulation of cellular growth Symbol log2 change
Cyclin D1 CCND1  1.03
v-fos FBJ murine osteosarcoma viral oncogene homolog FOS -1.6
Mitogen-activated protein kinase kinase kinase 8 MAP3K8 -1.2
Growth differentiation factor 8 (myostatin) GDF8 (MTSN) -2.72
Uncoupling protein 2 (mitochondrial, proton carrier) UCP2  1.4
WNT1 inducible signaling pathway protein 1 WISP1  1.04
All experiments were performed in duplicate. The expression levels were normalized to five internal control genes, log2 change was calculated 
as -ΔΔCt.
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matching tumor-derived and normal tissue-derived MF pairs 
were subjected to a scratch wound assay and RNA extraction 
to determine migration activity and MMP expression levels. 
Pair-wise comparisons of tumor- and normal tissue-derived 
MFs revealed that tumor‑originating MFs migrated signifi-
cantly more compared their normal counterparts (P<0.01; 
Fig. 4A and B). Using these MF cultures, differences were 
demonstrated in the expression levels of various MMPs 
(represented as fold-change in Fig. 4C), proteases that can 
modulate cell‑matrix interactions and facilitate cell mobiliza-
tion, between stromal and normal MFs. A rather analogous 
behavior of tumor-residing MFs within the whole gastrointes-
tinal tract is represented, therefore, it is feasible to suggest that 
these traits acquired by MFs in the tumor microenvironment 
can in fact develop generally in the tumor stroma and are not 
restricted to one single patient. Although patient-to-patient 
individual variations cannot be excluded, similar acquired 
features of stromal MFs in esophagus, cecum, sigmoid colon 
and rectum tumor have been demonstrated.
Discussion
MFs are important stromal cells that define the tumor tissue 
microenvironment through secretion of ECM components, 
growth factors, cytokines, proteases and protease inhibi-
tors (25,26). Through direct or indirect actions between MFs 
and transformed cancer cells the newly established niche 
supports the active remodeling of the physical environment, 
which will ultimately stimulate cancer cell proliferation and 
dissemination (27). The functional features of tumor-residing 
MFs are currently studied extensively, nonetheless, knowledge 
on the genetic and epigenetic background, as well as on the 
transcriptomic features of the evolving stromal MF phenotypes 
remains limited. A comparative analysis of MFs obtained from 
the tumor tissue and from tumor-adjacent normal tissue of an 
esophageal cancer patient was performed, in order to identify 
specific features of the exhibited MF phenotype in the tumor 
microenvironment. Finally, specific acquired features on 
other gastrointestinal tract tumor‑derived MFs were verified. 
Appropriate examination of MF‑specific properties required 
the establishment of pure MF cell cultures from surgically 
resected human samples.
To gain information on the genetic status of stromal MFs, 
next generation sequencing was performed to detect the occur-
rence of nucleotide variants in a set of most frequently mutated 
cancer genes. As expected, over 255 kbp (~1 variant per kbp) 
was demonstrated. Among these, normal tissue-derived and 
tumor-associated MFs carried 22 relevant germline SNPs 
(Table I) predicted to be functionally significant. A few genes 
(ERCC5, BRCA2, MSH6 and SLX4) were affected by more 
than one SNP. A total of 4 variants were also identified that 
were present only in tumor-associated MF samples and 11 vari-
ants that were present in the tumor tissue but not in the adjacent 
normal MF samples (Table II). The TP53 that were detected to 
be present with 14.92% allele frequency in the tumor tissue has 
already been associated with tumors in various primary sites 
including the esophagus (reference in ClinVar database).
The genetic analysis in the present study indicated low 
occurrence of somatic variants in tumor-associated MF 
samples and that normal tissue- and tumor-derived MFs carry 
Figure 3. Expression and activity of matrix metalloproteases and migration 
capacity of tumor‑associated MFs. Quantitative polymerase chain reaction 
(A) data demonstrates the expression of MMP1, MMP2, MMP3, MMP10 
and MMP12 in the tumor-derived MFs and in the control cells. The 
expression levels were normalized to the expression of the control sample. 
Expression of MMP3, MMP10 and MMP12 was significantly elevated in 
tumor-derived MFs compared to control cells. ****P<0.0001 and **P<0.01; 
two way ANOVA followed by Tukey's HSD post hoc multiple comparison 
test. No difference was observed for MMP1 and MMP2 expression. 
In‑gel zymography was performed on tumor‑associated and control MFs 
to determine MMP gelatinase activity (B). Slight difference in MMP2 
enzyme activity was detected between tumor‑derived and adjacent normal 
MF cell lysates. However, MMP2 activity was markedly higher in condi-
tioned cell media of tumor-associated MFs compared with that of normal 
tissue‑derived MFs. On the representative zymograms the upper band 
reflects the zymogen form of MMP2 (proform), while the lower band cor-
responds to the active form of MMP2. No MMP9 activity was detected 
in either MF culture. Migratory capacity of tumor-associated and adjacent 
normal tissue-derived MFs was assessed by wound healing assay (C). Cells 
that migrated into the wound area were counted 24 h following scratching. 
Motility of the normal MFs was defined as 100%. Migration capacity of 
tumor‑derived MFs was significantly higher compared with normal cells 
(153.09±2.12 vs. 100±2.39) indicated by the summarized migration rate. 
***P<0.001; Student's t‑test. MMP, matrix metalloproteinase; MF, myofi-
broblast.
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similar numbers of unique somatic mutations, suggesting that 
mutation frequency is not elevated drastically in tumor-asso-
ciated MFs.
This lack of notable genetic alterations in tumor-associated 
compared with the control MFs suggests that genetic varia-
tions most probably cannot explain the observed differences, 
including the largely elevated MF number, the severely 
damaged MF architecture and the meshwork-like structures 
created by tumor-residing MFs. Instead, in light of these data, 
epigenetic mechanisms are responsible for the emergence of 
the stromal MF phenotype. Indeed, global DNA hypomethyl-
ation that may have a relevant role in cancer progression has 
already been demonstrated in cancer-associated MFs (28).
It is well-known, that in addition to DNA methylation, 
alterations in the acetylation or methylation level of specific 
lysine (K) side chains of histone proteins, established by 
histone modifying enzyme complexes, can lead to chromatin 
modifications, thereby to major variations in the gene expres-
sion pattern and consequently to morphological, and functional 
alterations of a given cell (29-31). Alterations in the global 
levels of numerous epigenetic histone marks were examined 
and shifts were detected in the level of specific acetylated 
and methylated histone proteins between normal tissue- and 
esophageal tumor-derived MFs. The observed alterations, 
including decreased levels of trimethylated H3K9 and acety-
lated H4K16 in tumor-associated MFs may affect chromatin 
Figure 4. Migration capacity and relative expression levels of various MMPs of tumor-derived and normal MF obtained from diverse regions of the gastroin-
testinal tract. Representative images of scratch wound assays demonstrated migration of MF cells into the wound area 24 h following scratching (A). Migration 
rate was calculated based on the number of MF cells in the wound zone and was normalized to the motility of the normal tissue‑derived MFs (B). Higher 
number of MFs could be counted within the wound area 24 h following scratching in the tumor-associated MF samples, therefore tumor-derived cells exhibited 
a greater migratory capacity compared with the normal MFs (**P=0.01 for cecum-derived MFs, ***P<0.001 for sigmoid colon-derived MFs and **P=0.002 for 
rectum-derived MFs, t-test). (C) Relative mRNA levels of matrix metalloproteases of tumor-associated and normal MFs. Tables demonstrate the relative expres-
sion of MMP1, MMP2, MMP3, MMP10 and MMP12 in the tumor-derived MFs compared with control cells based on quantitative polymerase chain reaction 
experiments. The expression levels of MMPs were defined as 1 for the control sample and the mRNA levels detected in tumor‑derived MFs are indicated as 
fold‑change. MMP, matrix metalloproteinase; MF, myofibroblast; T, tumor‑associated; N, normal.
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structure, which can at least partly serve as the underlying 
cause of the altered morphology of tumor-derived MFs.
In transformed cells, alterations in the expression of 
hundreds of genes occur throughout tumorigenesis and 
tumor invasion (32-34). Although MFs are non-transformed 
cells, their expressional profile is expected to adapt to the 
undergoing morphological and functional alterations within 
the tumor microenvironment (35,36). Elevated gene expres-
sion level of CCND1 were observed in tumor-derived MFs 
compared with normal MFs. Significantly increased expres-
sion of CCND1 has previously been identified in stromal 
fibroblasts of patients with invasive breast cancer, character-
ized by enhanced cancer growth, restrained apoptosis and poor 
patient outcome (37). In the present study it was hypothesized 
that the observed increased level of the CCND1 transcript is 
correlated with the elevated number of MF cells within the 
tumor tissue. Similarly, WISP1, a downstream component 
in the WNT1 signaling pathway [believed to be relevant to 
malignant transformation (38)] was also expressed at a high 
level in MF cells isolated from the tumor. The encoded protein 
attenuates p53-mediated apoptosis and binds to members of 
small leucine-rich proteoglycans present in the ECM therefore 
preventing the inhibitory activity of decorin and biglycan in 
tumor cell proliferation (39,40). The modulation of apoptotic 
mechanisms in tumor residing MFs is also indicated by the 
altered expression of apoptosis-associated BCL2 and FOS in 
these cells. The increased expression of UCP2, a critical regu-
lator of cellular metabolism, involved in the tumor-promoting 
metabolic shift during cell transformation (41), is also detect-
able in MFs. These cells must also participate in the complex 
metabolism of the tumor tissue by promoting cancer cells to 
overcome energy depletion due to the Wartburg effect. Finally, 
expression of hypoxia- and angiogenesis-linked ENPP2, 
HO‑1 and PTN genes were decreased in tumor-derived MFs 
compared with normal counterparts (Table III). PTN is 
a small secreted cytokine and it has a potent role in tumor 
growth progression, therefore, lower level of PTN mRNA in 
tumor-associated compared with normal MFs was somewhat 
surprising, however a study on prostate tumor CAFs reported 
a similar results (42).
Although TGFβ signaling can drive tumorigenesis and it is 
also the most capable factor in controlling MF differentiation, 
proliferation, and the interactions with the cellular microen-
vironment (43,44), notable differences were not demonstrated 
between MFs of different origins in the expression of TGFβ 
signaling pathway components. The only member of the TGFβ 
protein family with lower levels of mRNA in tumor-derived 
MFs corresponded to the secreted growth differentiation factor 
GDF8/MSTN. This protein is a negative regulator of skeletal 
muscle development and its high expression is associated with 
cancer cachexia (45). Decreased level of MSTN was also detect-
able in higher grade breast cancers and MSTN supplementation 
reduced the viability, and the migratory capacity of MCF-7 
breast adenocarcinoma cell line (46). Furthermore, lower levels 
of mRNA corresponding to MAP3K8 in tumor-associated MFs. 
This observation is also in agreement with previous results on 
the altered secretory profile of intestinal MFs of MAP3K8 
mutant mice, developing increased numbers and sizes of 
tumors, associated with enhanced epithelial proliferation and 
decreased apoptosis (Table III).
In tumor-derived MFs expression differences of various 
genes associated with metastasis were also observed. Among 
these, increased expression of EDN1 in tumor-derived MFs 
has been verified. EDN1 is a metastasis-involved secreted 
peptide exhibiting a strong stimulatory activity on cancer 
and stromal cell proliferation and migration within the tumor 
microenvironment (47). A low expression level of HMOX1 
was detected in MFs originating from the tumors. As HMOX1 
is a negative regulator of EDN 1 production, this lower expres-
sion of HMOX1 can explain the increased transcript levels of 
EDN1 (48). Like EDN1, elevated expression of MMP3 and 
PLAU has been detected in tumor-associated MFs compared 
with normal tissue-derived MFs (Table III). These two genes 
encode secreted zinc and serine protease enzymes, which 
following activation are partly responsible for the degradation 
of a number ECM proteins, including fibronectin, laminin, 
collagens, further supporting the active assistance of stromal 
MFs in tumor dissemination and metastasis (49). On the other 
hand, TaqMan array data indicated lower transcript levels of 
LYPD3 in tumor-derived MFs, which is not surprising in the 
view of a recent study on the differential diagnosis of epithelial 
malignancies, where the authors revealed that LYPD3 expres-
sion is elevated only in esophageal squamous cell carcinoma, 
but not in adenocarcinoma derived from esophagus tissue (50). 
Also in agreement with a previous study, lower expression of 
the chemokine CXCL12 was exhibited in tumor-derived MFs, 
demonstrated to be a prominent feature of clinical breast 
cancer lesions and together with elevated CXCR7 levels it 
correlated significantly with poor survival (51).
Tumor cells adopt the ability to migrate from the primary 
tumor site by becoming motile and obtain plasticity to mechan-
ically navigate the tumor stroma. The invasion process requires 
enzymes capable of remodeling the ECM protein scaffold to 
make room for cancer cell movement. The production of ECM 
remodeling proteases promotes cell invasion and motility by 
the dynamical degradation of the pericellular ECM (52). When 
activated, these proteases, including MMPs, cleave basement 
membrane components and multiadhesion proteins. In this way, 
MMPs can modulate cell-matrix interactions and facilitate cell 
mobilization, which ultimately supports cell migration (53,54). 
In fact, strong correlation has already been proposed between 
elevated expression levels of certain MMPs in tumor tissues and 
advanced tumor stages (TNM grading), increased metastasis, 
and poor prognosis (16,17). Based on the mRNA expression, 
as well as on the activity of various MMPs, a modified MMP 
profile of tumor‑derived MFs compared to normal MFs was 
observed. Furthermore, strongly correlated with the altered 
expression and secretion of proteases it was demonstrated that 
the tumor-derived MFs also migrated more compared with their 
normal counterparts, revealing another acquired functional 
feature of the tumor-residing MF phenotype. These results on 
altered MMP expression and enhanced migration of stromal 
MFs have been supported and strengthened by tumor- and 
normal tissue-derived MF pairs obtained from other regions 
of the gastrointestinal tract, namely from the cecum, sigmoid 
colon and rectum. Therefore, it is feasible to suggest that MFs 
in the tumor microenvironment assist cancer cell movement 
and by acquiring migratory capacity, these stromal cells have 
the potential to move collectively with cancer cells to promote 
the invasiveness of cancer cells in the tumor leading edge (55).
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Taken together, the results of the present study indicate that 
the observed morphological, gene expressional and concomitant 
functional alterations of MFs in the tumor microenvironment 
are definitely not due to genetic alterations but are more prob-
ably associated with epigenetic modifications. Nonetheless, 
similarly to other attempts trying to correlate histone modifica-
tions with altered RNA production level a careful analysis is 
warranted to distinguish causes and consequences.
In conclusion, in the present study human MFs obtained 
from gastrointestinal cancers were compared with those 
residing in adjacent normal tissue of individual patients to 
identify features of the exhibited MF phenotype that were 
acquired in the tumor microenvironment. MF cells were 
analyzed for differences in morphology, gene expression 
profile and function with the aim to associate observed varia-
tions with underlying genetic and/or epigenetic differences. It 
was demonstrated that mutation frequency was not elevated in 
tumor-derived MFs. Histone acetylation and methylation on 
the other hand can be more relevant in the development of gene 
expressional and functional alterations during the evolution of 
the stromal MF phenotype. The results of the present study 
also demonstrated that though correlations between transcrip-
tional, functional and epigenetic results can be drawn, general 
conclusions have to be considered very carefully. Since the 
present study directly compared features of MFs of normal 
and tumor tissues of various gastrointestinal cancer patients, 
it was hypothesized that the present study's results are a valu-
able contribution to the knowledge on the impact of MFs in 
supporting tumor progression.
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